Table 1.
Baseline Patient Characteristics for Newly Initiated Allopurinol Users
| Total Incident Allopurinol Users | N= 13,341 |
| Follow-up Duration, years (mean, SD) | 3.27±1.55 |
| Male, (n,%) | 10,410 (78.0) |
| Age, years (mean, SD) | 60.2±13.9 |
| BMI kg/m2 (mean, SD) | 31.5±6.6 |
| Race/Ethnicity (n,%) | N= 13,341 |
| Caucasian | 5,469 (41.0) |
| African American | 2,089 (15.7) |
| Hispanic | 2,608 (19.5) |
| Asian/Pacific Islander | 3,086 (23.1) |
| Other | 89 (0.7) |
| Comorbidities (n,%) | N= 13,341 |
| Hypertension | 9,449 (70.8) |
| Myocardial infarction | 905 (6.8) |
| Congestive heart failure | 1,047 (7.8) |
| Diabetes | 3,124 (23.4) |
| Laboratory Data | |
| Patients with a Baseline eGFR Lab Level (n,%) | N= 11,352 (85.1) |
| Baseline eGFR level, ml/min (mean, SD) | 63.5±18.5 |
| CKD Stage 1, eGFR ≥ 90 ml/min, (n, %) | 1,487 (13.1) |
| CKD Stage 2, eGFR 60-89 ml/min, (n, %) | 5,171 (45.6) |
| CKD Stage 3, eGFR 30-59 ml/min, (n, %) | 4,286 (37.8) |
| CKD Stage 4, eGFR 15-29 ml/min, (n, %) | 426 (3.8) |
| Patients with a Baseline sUAa (n,%) | N= 11,645 (87.3) |
| Baseline sUA, mg/dl (mean, SD) | 8.58±1.8 |
| Concomitant Medication Use with Initial Allopurinol | |
| Diuretic Use (n, %) | N= 5,212 (39.1) |
| Loop diuretics | 1,094 (8.2) |
| Thiazides diuretics | 3,750 (28.1) |
| Anti-inflammatory medications (n,%)b | |
| NSAID | 4,842 (36.3) |
| Corticosteroid | 2,816 (21.1) |
| Colchicine | 5,073 (38.0) |
| Any of above | 9,222 (69.1) |
a
Serum urate evaluated 12 months prior and up to 30 days after allopurinol dispensing
b
patients could be prescribed more than two anti-inflammatory medications; anti-inflammatory use was extracted from the period covering 30 days prior and up to 30 days after the index allopurinol dispensing.
Standard deviation (SD); body mass index (BMI); estimated glomerular filtration rate (GFR); chronic kidney disease (CKD); serum urate (sUA); Non-steroidal anti-inflammatory drug (NSAID).